By Turna Ray

Vying to break into the point-of-care testing market to guide anti-platelet treatment in cardiac patients, at least two molecular diagnostics companies are studying the utility of their rapid tests in clinical trials.

Spartan Bioscience announced this week that researchers at the University of Ottawa Heart Institute are using its Spartan RX point-of-care testing system to gauge CYP2C19 mutations that may impair cardiac patients' response to Bristol-Myers Squibb's anti-clotting drug Plavix.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.